Peptilex – The Peptide Encyclopedia
- 34 peptides – from semaglutide to BPC-157 – in one book
- An evidence grade (A–E) and the key studies for every peptide
- Where each one stands in 2026 – US, EU and Switzerland
Healing & recovery
KPV
- Type
- Tripeptide (lysine–proline–valine), the end fragment of alpha-MSH
- Main use or focus
- Inflammatory bowel disease, skin inflammation
Key studies from the book
Cells and mouse colitis; KPV taken up through the PepT1 transporter reduced intestinal inflammation.
Dalmasso G et al. – Gastroenterology, 2008Two mouse models of colitis; faster recovery and less inflammation.
Kannengiesser K et al. – Inflammatory Bowel Diseases, 2008
All key studies, risks and open questions are in the book.
Research at a glance
All papers52
Human studies28
Animal studies only14
Randomized trials0
Meta-analyses & systematic reviews0
Source: PubMed and ClinicalTrials.gov via the Peptilex study database
Go deeper
Full profile in the book
What it is, how it acts, the key studies, risks and open questions.
Registered trials
ClinicalTrials.gov · name in study title · ongoing first
No registered trial yet on ClinicalTrials.gov.
Latest key papers
PubMed · newest first
- 2024
KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy
Human studyZhang L et al. · Advanced Healthcare MaterialsPMID 39252648
- 2022
A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon
Animal studyZhao Y et al. · Acta BiomaterialiaPMID 35245681
- 2021
Animal studySun J et al. · ACS Biomaterials Science & EngineeringPMID 34547895
- 2008
Animal studyKannengiesser K et al. · Inflammatory Bowel DiseasesPMID 18092346
- 2003
Animal studyGetting SJ et al. · The Journal of Pharmacology and Experimental TherapeuticsPMID 12750433